Skip to main content

Table 1 Baseline characteristics of 140 HIV-infected patients

From: Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Prior Co-administration of Rifampicin: A 144-week Prospective Study

Characteristics

Total (n = 140)

TB Group (n = 70)

Control Group (n = 70)

Pvalue

Gender: Male

95 (68%)

56 (80%)

39 (56%)

0.002

Age, years, mean ± SD

35.7 ± 7.6

34.4 ± 6.2

37.2 ± 8.7

0.028

Body weight, Kgs, mean ± SD

54.6 ± 9.6

54.7 ± 8.7

54.4 ± 10.6

0.827

Body mass index, mean ± SD

20.1 ± 2.9

19.7 ± 2.4

20.5 ± 3.4

0.097

CD4 cell counts, cells/mm3, mean ± SD

62 ± 74

61 ± 74

76 ± 75

0.823

%CD4, median (IQR)

5 ± 5

6 ± 5

5 ± 5

0.226

Plasma HIV RNA, copies/ml, median (IQR)

433,500 (169,000–750,000)

505,000 (269,000–750,000)

291,000 (94,600–714,000)

0.014

Plasma HIV RNA, Log copies/ml, median (IQR)

5.6 (5.2–5.9)

5.7 (5.4–5.9)

5.6 (5.0–5.9)

0.004

ALP, mg/dl, median (IQR)

98 (71–142)

110 (75–154)

91 (70–128)

0.072

AST, U/l, median (IQR)

30 (20–50)

36 (27–60)

35 (26–47)

0.371

ALT, U/l, median (IQR)

27 (19–42)

27 (18–51)

32 (22–49)

0.169

Total bilirubin, mg/dl, median (IQR)

0.6 (0.4–0.7)

0.6 (0.5–0.8)

0.5 (0.4–0.7)

0.051

  1. IQR = interquartile range